Sign in
TerminatedPhase 2

Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep

Key facts

Who runs it
Neurocrine Biosciences
Where
Aurora, Cleveland, Durham, Miami, Orange, Rochester, and Washington D.C., United StatesSee the 7 sitesAlso in 4 other countries, 5 sites
Status
Terminated
Phase
Phase 2
People taking part
19 people enrolled
Started
7 Jun 2022
Ended
27 Jan 2025
Type of study
Interventional
Treatments tested
  • NBI-827104
Record updated
13 February 2026
Why it stopped
Business decision

Who can take part

Age
4 years to 12 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • For participants who enroll directly following the completion of the Study NBI-827104-CSWS2010:
  • Completed 12 weeks of treatment in Study NBI-827104-CSWS2010; For Participants Who Do Not Enroll Directly from or Did Not Participate in Study NBI-827104-CSWS2010:
  • Have diagnosis of EECSWS confirmed by the Diagnosis Confirmation Panel (DCP)

Who cannot take part

  • Presence of relevant neurological disorders other than EECSWS and its underlying conditions as judged by the investigator. Symptomatic conditions underlying EECSWS (for example, neonatal strokes) have to be stable for at least 1 year prior to screening
  • Planned surgical intervention related to structural abnormalities of the brain from screening through the Week 6 Visit
  • Used any active investigational drug other than NBI-827104 in the context of a clinical study within 30 days or 5 half-lives (whichever is longer) before screening or plans to use such an investigational drug (other than NBI-827104) during the study
  • Have developed any other disorder for which the treatment takes priority over treatment of EECSWS or is likely to interfere with study treatment or impair treatment compliance; For Participants Who Do Not Enroll Directly from or Did Not Participate in Study NBI-827104-CSWS2010:
  • Have developed any other disorder for which the treatment takes priority over treatment of EECSWS or is likely to interfere with study treatment or impair treatment compliance
  • Clinically relevant findings related to cardiovascular or laboratory parameters at screening as determined by the investigator
  • For participants who enroll directly following the completion of the Study NBI-827104-CSWS2010:
  • Body weight <15 kg at Day 1

Where in United States

Also in 4 other countries, 5 sites

  • Aurora, ColoradoHospital not named in the registry
  • Cleveland, OhioHospital not named in the registry
  • Durham, North CarolinaHospital not named in the registry
  • Miami, FloridaHospital not named in the registry
  • Orange, CaliforniaHospital not named in the registry
  • Rochester, New YorkHospital not named in the registry
  • Washington D.C., District of ColumbiaHospital not named in the registry

About the trial

What the trial wants to find out

The primary objective for this study is to evaluate the long-term safety and tolerability of NBI-827104 in pediatric participants with epileptic encephalopathy with continuous spike-and-wave during sleep (EECSWS).

The group in the trial

  • NBI-827104Treatment being tested

    NBI-827104 administered orally

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Long-Term, Open-Label Extension Study to Evaluate the Safety and Tolerability of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep
Record updated
13 February 2026